Skip to main content
. 2023 Apr 29;17(8):1581–1594. doi: 10.1002/1878-0261.13439

Fig. 1.

Fig. 1

The flow chart of patient enrolment and validation cohorts. A total of 107 NSCLC patients harbouring HER2 mutations were enrolled in the GLCI cohort, including 76 patients with HER2 ex20ins and 31 patients with HER2 non‐ex20ins mutations. The efficacy of ICI‐based therapy and TME features were investigated among 35 of these 107 patients (GLCI‐ICI cohort). Two external datasets of HER2‐mutated NSCLC patients, The Cancer Genome Atlas Program (TCGA, n = 21) and META‐ICI (n = 30) were used for result validation.